ID NO:3) and SV40-2 (SEQ ID NO:4) which comprise *Sal* I cloning sites to facilitate sub-cloning of the amplified DNA fragment into pCMV.cass. The primer also contains a synthetic poly (A) site at the 5' end, such that the amplification product comprises the synthetic poly(A) site at the 5' end of the SV40 promoter sequence.--.

On page 45 4th paragraph (line 24) through page 46, (line 5), please replace the paragraph with the following: --The BEV RNA-dependent RNA polymerase coding region was amplified as a 1,385 bp DNA fragment from a full-length cDNA clone encoding same, using primers designated BEV-1 (SEQ ID NO:5) and BEV-2 (SEQ ID NO:6), under standard amplification conditions. The amplified DNA contained a 5'-*Bgl* II restriction enzyme site, derived from the BEV-1 primer sequence (SEQ ID NO:5) and a 3'*Bam*HI restriction enzyme site, derived from the BEV-2 primer sequence (SEQ ID NO:6). Additionally, as the BEV-1 primer sequence (SEQ ID NO:5) contains a translation start signal 5'-ATG-3' engineered at positions 15-17, the amplified BEV polymerase structural gene comprises the start site in-frame with BEV polymerase-encoding nucleotide sequences, Thus, the amplified BEV polymerase structural gene comprises the ATG start codon immediately upstream (ie. Juxtaposed) to the BEV polymerase-encoding sequence. There is no translation stop codon in the amplified DNA. This plasmid is present as Figure 9.--.

On page 46, 2nd paragraph (lines 17-25), please replace the paragraph with the following: --A non-translatable BEV polymerase structural gene was amplified from a full-length BEV polymerase cDNA clone using the amplification primers BEV-3 (SEQ ID NO:7) and BEV-4(SEQ ID NO:8). Primer BEV-4 comprises a *Bgl*II cloning site at positions 5-10 and sequences downstream of this *Bgl*II site are homologous to nucleotide sequences of the BEV polymerase gene. There is no functional ATG start codon in the amplified DNA product of primers BEV-3 (SEQ ID NO:7) and BEV-4 (SEQ ID NO:8). The BEV polymerase is expressed as part of a polyprotein and, as a consequence, there is no ATG translation start site in this gene. The amplified DNA was cloned into plasmid pR2.1 (Stratagene) to yield plasmid pCR.BEV.3 (Figure 11).

On page 57, paragraphs 5 and 6 (lines 12-16), please replace the paragraph with the following:

--NOS 5' (forward primer; SEQ ID NO:9)

5'-GGATTCCCGGGACGTCGCGAATTTCCCCCGATCGTTC-3'; and

B5 CONT

NOS 3' (reverse primer; SEQ ID NO:10)

5'-CCATGGCCATATAGGCCCGATCTAGTAACATAG-3'--.

On page 60, paragraph 3 (lines 9-11), please replace the paragraph with the following:

B6 SUB C1

--LNYV 1:5' ATGGGATCCGTTATGCCAAGAAGAAGGA-3' (SEQ ID NO:11); and

LNYV 2:5' ATGGGATCCGTTATGCCAAGAAGAAGGA-3' (SEQ ID NO:12)--.

On page 66, paragraph 2 (lines 9-15), please replace the paragraph with the following:

B7 SUB C2

--PVY 1:

5'TAATGAGGATGATGTCCCTACCTTTAATTGGCAGAAATTTCTGTGGAAAGACAGGG AAATCTTTCGGCATTT-3' (SEQ ID NO:13); and

PVY 2:

5' TTCTGCCAATTAAAGGTAGGGACATCATCCTCATTAAAATGCCGAAAGATTTCCCT GTCTTTCCACAGAAAT-3' (SEQ ID NO:14)--.

IN THE SEQUENCE LISTING:

Please cancel from the application Original Sequence Listing pages 1-7 and substitute therefore the attached Replacement Sequence Listing pages 1-4.

REMARKS

This Supplemental Preliminary Amendment and Response to Notice to Comply brings the patent application into compliance with the Sequence Listing Disclosure requirement of the USPTO. Enclosed herewith are: (1) A paper copy of the Replacement Sequence Listing, (2) and a computer readable version of the Replacement Sequence Listing. The Response to Notice to Comply directs entry of the paper copy of the Sequence listing into the application. In view of the foregoing, the application is believed to fully comply with the Sequence Listing Disclosure requirements.

The changes made to the claims by the current amendment, including **[deletions]** and additions, are shown on an attached sheet entitled **VERSION WITH MARKINGS TO SHOW CHANGES MADE**, which follows the signature page of this amendment.

VERIFICATION UNDER 37 C.F.R. §1.821(f) & (g)

All of the sequences in the attached Sequence Listing were included in the application as filed. Pursuant to 37 C.F.R. §1.821(g), no new matter is being added herewith. As required under 37 C.F.R. §1.821(f), I hereby verify that the data on the enclosed disk and the paper copies of the Sequence Listing are identical.